The Clinical Utility of Thrombelastography in Guiding Prophylaxis of Venous Thromboembolism Following Trauma (VTEPX)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01050153|
Recruitment Status : Completed
First Posted : January 15, 2010
Results First Posted : April 25, 2014
Last Update Posted : January 8, 2019
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
This study plans to learn more about how to prevent blood clots in the veins of your extremities. You are at risk of forming these clots after a major injury and when you have had surgery and are hospitalized on bed rest.
Usually, patients in the SICU at Denver Health who are at risk for blood clots receive preventative treatment with a FDA-approved medicine called Fragmin. Fragmin is intended to prevent blood clots from forming but, with the way it is generally used, some patients may still develop blood clots. All patients treated with Fragmin to prevent blood clots at Denver Health, currently receive the same Fragmin dose. This treatment is called the "standard of care".
So far, in the US, there has not been a commonly available test that can tell us:
- if the standard dose of Fragmin is enough to prevent blood clots for everyone, or
- if different patients need different doses, or
- if other blood clot preventing medicines, that work in a different way, should be used in addition to Fragmin.
The ability of your blood to clot and the strength of the clot formed can be described by a FDA-approved blood test called thrombelastography, referred to as TEG. TEG may provide us with answers to each of the questions above. Our preliminary data indicate that it is helpful in assessing both clotting and bleeding tendencies and may prove useful in guiding treatment for the prevention of blood clots.
The aim of this study is to determine if a treatment plan using Fragmin, and, if indicated, one or two additional FDA-approved medicines called anti-platelet drugs, guided by the results of TEG testing, may be better at preventing blood clots than our current standard of care.
|Condition or disease||Intervention/treatment||Phase|
|Venous Thromboembolism||Drug: Dalteparin sodium Drug: Dalteparin sodium/aspirin||Not Applicable|
This preliminary/pilot study involves a prospective, randomized, open-label, parallel group comparison of Denver Health's current standard of care for prevention of venous thromboembolism (VTE), commonly known as blood clots, using LMWH (Fragmin) 5000IU subcutaneously daily, with a thrombelastography (TEG)-guided, algorithm-based, individualized regimen of LMWH (Fragmin) plus/minus anti-platelet therapy (aspirin) guided by platelet mapping, in patients admitted to the SICU following trauma.
Approximately 50 trauma patients for whom prevention of VTE with LMWH is indicated, will be enrolled over a six month period.
The specific aims of this study are as follows:
- To determine the incidence of, and to characterize, hypercoagulability using TEG and conventional clinical coagulation testing (APTT, INR), Antithrombin III levels and Protein C activity.
In the group of patients receiving LMWH (Fragmin) therapy alone for prevention of VTE:
- to assess the anticoagulant effect of standard LMWH (Fragmin) dosing (5000IU subcutaneously once daily) using TEG and Anti-Factor Xa level measurement, and
- to determine the extent of correlation of relevant TEG parameters with measured Anti-Factor Xa levels (U/ml).
- To assess whether TEG is a useful clinical tool for monitoring and optimizing prophylactic LMWH (Fragmin) therapy and for identifying the need for anti-platelet therapy to minimize the risk of VTE in these patients.
- To evaluate the clinical utility of platelet mapping for guiding anti-platelet therapy in those patients for whom it is indicated by TEG results.
- To determine the incidence of deep vein thrombosis (DVT) and pulmonary embolism (PE) in each randomized group and in the subgroup receiving anti-platelet therapy in addition to LMWH (Fragmin) for prevention of VTE.
The overall aim is to utilize the above data to evaluate a) the adequacy of our standard Fragmin dosing regimen (5000IU subcutaneously once daily) alone for prevention of VTE in our trauma/SICU patients, b) the need for anti-platelet agents in addition to LMWH (Fragmin) for prevention of VTE in our population, and c) to validate/further develop the TEG-guided algorithm for optimal prophylaxis of VTE using LMWH (Fragmin) plus/minus anti-platelet therapy guided by platelet mapping.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||50 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||An Evaluation of the Clinical Utility of Thrombelastography (TEG) in Guiding Low Molecular Weight Heparin (LMWH) and Antiplatelet Prophylaxis of Venous Thromboembolism (VTE) Following Trauma|
|Study Start Date :||March 2010|
|Actual Primary Completion Date :||December 2011|
|Actual Study Completion Date :||December 2011|
Active Comparator: Control (standard of care)
Dalteparin sodium 5000IU subcutaneously daily
Drug: Dalteparin sodium
Dalteparin sodium injection 5000IU subcutaneously daily until fully ambulatory
Other Name: Dalteparin sodium (Fragmin)
Experimental: TEG-guided thromboprophylaxis
Dalteparin sodium plus/minus anti-platelet medication (aspirin) per a TEG-guided algorithm
Drug: Dalteparin sodium/aspirin
Dalteparin sodium (2500-10,000IU sc daily), aspirin (81-325mg daily) po.
Other Name: dalteparin sodium (Fragmin)
- Hypercoagulability [ Time Frame: Study day five. ]To determine the incidence of, and to characterize, hypercoagulability in a sample of trauma patients admitted to the SICU at DHMC using TEG and conventional clinical coagulation testing (APTT, INR), antithrombin III levels and protein C activity. Hypercoagulability is defined as TEG parameter G (clot strength) >10.9.
- Incidence of VTE [ Time Frame: Day 28 or discharge, whichever comes first. ]The incidence and nature of hypercoagulability and the incidence of deep vein thrombosis and pulmonary embolism in each randomized group and in the subgroup receiving anti-platelet therapy in addition to Fragmin (descriptive analysis only)
- TEG Parameters [ Time Frame: Study day five. ]
R is a reaction time. The time from the start of a sample run until the first significant levels of detectable clot formation (amplitude = 2 mm in the TEG tracing).
Rf is a difference in reaction time between Fragmin-active and Fragmin-neutralized samples.
Achievement of a certain clot strength K is a measure of the time from R until a fixed level of clot strength is reached (amplitude = 20 mm).
Angle or α measures the rapidity of fibrin build-up and cross-linking (clot strengthening). This most represents fibrinogen level. Angle relates to K, since both are a function of the rate of clot formation.
MA, or Maximum Amplitude, is a direct function of the maximum clot strength. In tests where platelets are part of the clot, this parameter most reflects platelet function/aggregation. Clot strength is the result of two components - the modest contribution of fibrin and the much more significant contribution of the platelets.
- International Normalized Ratio (INR) [ Time Frame: Study day five. ]Plasma based conventional coagulation testing parameters
- Platelet Count [ Time Frame: Study day five. ]Platelet count measured by CBC test
- TEG Parameters [ Time Frame: Study day five. ]
Shear elastic modulus strength (SEMS). The MA parameter can be transformed into the actual measure of clot strength (G) using the formula below, and is measured in dyn/cm2 divided by 1000 (displayed in the software as Kd/sc).
The absolute SEMS of the sample can be calculated from MA as follows:
G = (5000MA/(100-MA))/1000 An amplitude of 50 mm corresponds to a SEMS of 5000 dyn/cm2. An increase in MA from 50 mm to 67 mm is equivalent to a two-fold increase in the SEMS. The G parameter not only provides a measurement of clot firmness in force units, but also is more indicative of small changes in the clot strength or clot breakdown than is the amplitude in mm because it is an exponential reflection of MA.
- Conventional Coagulation Testing Parameters [ Time Frame: Study day five. ]Plasma based conventional coagulation testing parameters - Anti Xa
- Conventional Coagulation Testing Parameters [ Time Frame: Study day five. ]Plasma based conventional coagulation testing parameters - Fibrinogen
- Conventional Coagulation Testing Parameters [ Time Frame: Study day five. ]Plasma based conventional coagulation testing parameters - Anti-thrombin III
- Conventional Coagulation Testing Parameters [ Time Frame: Study day five. ]Plasma based conventional coagulation testing parameters - Protein C
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- age at least 18 years,
- blunt or penetrating trauma requiring admission to the SICU
- requirement for LMWH (Fragmin) therapy for prophylaxis of VTE as standard of care, and
- informed consent by patient, legally authorized representative or proxy decision maker (if patient incompetent to provide) obtained and documented.
Presence of any of the following absolute contraindications to LMWH (Fragmin) therapy:
- known hypersensitivity to dalteparin sodium,
- known hypersensitivity to heparin or pork products,
- thrombocytopenia associated with positive tests for antiplatelet antibody in the presence of Fragmin,
- history of heparin-induced thrombocytopenia (HIT),
- chronic liver disease (bilirubin >2 mg/dl) or kidney insufficiency (CrCl <30mL/min),
- intravascular thrombolytic therapy within 24 hours,
- resuscitation that required massive transfusion (>10 units RBC within 6 hours),
- ongoing resuscitation for hemorrhagic shock,
- known bleeding disorder or coagulopathy (INR >2 not on warfarin),
- thrombocytopenia (platelets <20K/uL),
- subdural or epidural hematoma.
Presence of any of the following relative contraindications to LMWH (Fragmin) therapy:
- new intracranial lesions, neoplasms or monitoring devices,
- extravascular thrombolytic therapy,
- severe uncontrolled hypertension,
- arterial dissection
- recent (within 12 hours) intraocular surgery (prior or planned),
- recent (within 72 hours) intracranial or spine surgery (prior or planned),
- conditions associated with increased risk of hemorrhage, e.g. active gastrointestinal ulceration, angiodysplastic disease, gastrointestinal bleeding within the past six months, bacterial endocarditis, history of hemorrhagic stroke, diabetic retinopathy.
Presence, or removal within the last 12 hours, of an indwelling epidural or spinal catheter, OR recent (within the last 12 hours) or planned neuraxial (spinal/epidural) anesthesia or spinal puncture.
Per history taken from patient or family, concomitant or known use within one week prior to hospitalization, of drugs affecting hemostasis such as NSAIDS, platelet inhibitors or other anticoagulants, except as specified in this protocol.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01050153
|United States, Colorado|
|Denver Health Medical Center|
|Denver, Colorado, United States, 80203|
|Principal Investigator:||Ernest E. Moore Jr, M.D.||Chief, Department of Surgery and Trauma Services , Denver Health Medical Center|
|Responsible Party:||Ernest E. Moore, MD, Chief, Department of Surgery and Trauma Services Rocky Mountain Regional Trauma Center, Denver Health and Hospital Authority|
|Other Study ID Numbers:||
COMIRB # 09-0753
|First Posted:||January 15, 2010 Key Record Dates|
|Results First Posted:||April 25, 2014|
|Last Update Posted:||January 8, 2019|
|Last Verified:||December 2018|
Prevention of venous thromboembolism
Embolism and Thrombosis
Anti-Inflammatory Agents, Non-Steroidal
Sensory System Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Fibrin Modulating Agents
Molecular Mechanisms of Pharmacological Action
Platelet Aggregation Inhibitors